business
Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricuspid Valve Replacement System
Summary by Denton News Editorial Desk By Laplace Interventional, Inc. , as published by Denton Record-Chronicle
· June 29, 2026
· 1 min read
Photo: Denton Record-Chronicle · view original
Story provenance No corrections
Summary created by Denton News Editorial Desk — automated, rule-governed Byline on source page By Laplace Interventional, Inc., as published by Denton Record-Chronicle Original story Read at the source Source published Jun 29, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key points The approval was announced on June 29, 2026, and marks a significant step forward for the company's Transcatheter Tricuspid Valve Replacement system. A medical device company has received approval from the US Food and Drug Administration for a pivotal trial.
A medical device company has received approval from the US Food and Drug Administration for a pivotal trial. The trial, called TRIUMPH, will evaluate a system for replacing the tricuspid valve in the heart using a transcatheter approach.
The system is being developed by Laplace Interventional, a company based in Minneapolis. The approval is for an Investigational Device Exemption, which allows the company to move forward with the trial.
Further details about the trial and the device are available from the company's announcement. The approval was announced on June 29, 2026, and marks a significant step forward for the company's Transcatheter Tricuspid Valve Replacement system.
More business Today’s briefing Local events
Why this matters
Local business news drives decisions about where to shop, where to invest, and where to apply for jobs. Denton News covers openings, closings, expansions, and economic shifts because each one ripples through the community.
About this story
As published by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: business Published: June 29, 2026 Source: Denton Record-Chronicle Reading time: 1 min
Frequently asked about this story
What is this story about? A medical device company has received approval from the US Food and Drug Administration for a pivotal trial. The trial, called TRIUMPH, will evaluate a system for replacing the tricuspid valve in the…
When was this published? This article was first published on June 29, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By Laplace Interventional, Inc. at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more business coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More business →
Today’s briefing
Subscribe to newsletter
